#For researchers
Written for academic and pharma-industry researchers; assumes domain literacy.
GLP-1 and bone loss from glucocorticoids
A July 2026 Stem Cell Reports paper shows GLP-1 shifts bone marrow stem cells toward bone via HIF-2alpha and AKT signaling in steroid-induced osteoporosis.
Tirzepatide dosing: what the trials used
A trial-by-trial map of the dose escalation schedules used across the SURPASS and SURMOUNT programmes, with what each schedule produced at the primary endpoint.
TB-500 dosing: what the trials used
The 2 mg weekly range circulating online has no human trial behind it. Here is what published thymosin beta-4 studies actually administered, trial by trial.
Semax dosing: what the trials used
Published Semax doses come from Russian stroke trials. No Western-standard human trial has validated any dose for other indications.
Semaglutide and OA: beyond weight loss
A 2026 preclinical study shows semaglutide reduces cartilage damage and joint pain without weight change, via GLP-1R activation of autophagy in chondrocytes.
Tesamorelin: what a cognition trial found
A 2026 pilot of low-dose tesamorelin found no significant changes on cognitive tests. Machine learning flagged shifts in two brain regions linked to attention.
Retatrutide: dose ranges from the trials
Two Phase 2 trials tested retatrutide from 0.5 mg to 12 mg weekly. Here is what each trial administered, trial by trial.
Semaglutide doses in published trials
Dose regimens from the STEP, SUSTAIN, and SELECT trials. All figures come from published protocols, not from prescribing guidance.
Semaglutide P29: a new production method
A 2026 PLoS ONE study reports 5.85 g/L yield and 98% purity for the semaglutide main-chain intermediate using a SNAC-tagged bacterial expression system.
BPC-157 dosing: what the studies used
No validated human dose for BPC-157 exists. The 200 to 500 mcg range quoted online is an allometric extrapolation from rodent injury models, not clinical data.